trimetazidine has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Binder, CJ; Brekalo, M; Fischer, MB; Goederle, L; Haider, P; Hengstenberg, C; Hohensinner, PJ; Huber, K; Kaun, C; Lenz, M; Mayer, J; Podesser, BK; Ramsmayer, D; Richter, M; Salzmann, M; Sharma, S; Speidl, WS; Stojkovic, S; Wojta, J | 1 |
| Avagimyan, A | 1 |
| Chen, M; Du, Y; Fan, X; Li, J; Peng, Q; Zheng, S | 1 |
1 review(s) available for trimetazidine and Atherogenesis
| Article | Year |
|---|---|
Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment.
Topics: Animals; Atherosclerosis; Endothelium; Homocysteine; Humans; Hyperhomocysteinemia; Rats; Rats, Wistar; Trimetazidine | 2022 |
2 other study(ies) available for trimetazidine and Atherogenesis
| Article | Year |
|---|---|
Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation.
Topics: Animals; Atherosclerosis; Cytokines; Fatty Acids; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Inflammasomes; Lipid Metabolism; Macrophages; Male; Mice; Mice, Knockout; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidation-Reduction; Receptors, LDL; Trimetazidine; Vasodilator Agents | 2021 |
Trimetazidine Protects Against Atherosclerosis by Changing Energy Charge and Oxidative Stress.
Topics: Animals; Aorta; Atherosclerosis; Cell Line; Cell Proliferation; China; Diet, High-Fat; Disease Models, Animal; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Myocytes, Smooth Muscle; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Reactive Oxygen Species; Superoxide Dismutase; Triglycerides; Trimetazidine | 2018 |